Posts by Sandra Ansanay-Alex
AB2 Bio Secures $30 Million as Nippon Shinyaku Exercises US Commercialization Rights for Tadekinig Alfa
AB2 Bio, a Swiss Health Valley and EPFL based company, has announced that Nippon Shinyaku has exercised its exclusive option to commercialize Tadekinig alfa in the United States, following positive exchanges with the FDA. Under the agreement, AB2 Bio will receive an upfront payment of $30 million and is eligible for up to $600 million…
Read MoreHeroSupport Starts Clinical Study With NYU Grossman School of Medicine
HeroSupport SA is a UNIGE and HUG spin out and created VENUS SHELL™ , a 3D-printed support that enables accurate, reproducible, and more comfortable positioning during radiation therapy for breast cancer patients. HeroSupport SA is advancing patient immobilisation in prone breast cancer radiotherapy. The CE-marked VENUS SHELL™ is a patient-specific, 3D-printed support that enables accurate,…
Read MoreImpli and Molesense Selected for Germany’s SPRIND Continuous Hormone Monitoring Challenge
MoleSense and Impli, two startups based at Biopôle near Lausanne, have both been selected by Germany’s Federal Agency for Breakthrough Innovation (SPRIND) for its Continuous Hormone Monitoring Challenge — a three-year programme backing biosensor technologies capable of tracking at least four hormones continuously over seven days, with up to €1.5 million in Stage 1 funding…
Read MorePlanimetrics Receives CHF 40,000 from Venture Kick
Planimetrics, formerly Laxiped, is a life-sciences project, spun out University of Geneva (UNIGE) and Assal Center, working on a solution to support foot and ankle surgeons diagnostics and decicion-making. First ray instability is a foot condition still diagnosed mainly through physical examination — a gap Planimetrics is working to close. The company has been awarded…
Read MoreThree Wins for the Swiss Health Valley: Recognition for Unboound, DIVERSSITY and Prof. Nicolas Winssinger
From clinical innovation to fundamental science, each of these Swiss Health Valley entrepreneurs and researchers were recognised at the highest level their respective field : ORL, AI-Driven Mental Health therapy and and Medicinal Chemistry. Dr. Julien Wen Hsieh wins the Grand Prix 2026 of the Swiss Society of ORL Dr. Julien Wen Hsieh, CEO and…
Read MoreMasimo Wins its Legal Battle Against Apple and is Set to Receive a Cheque for $634 million
Masimo, which has been headquartered in Neuchâtel since 2008 and employs over 100 staff there at the heart of the Swiss Health Valley, has just won one of the most closely watched legal cases in the technology industry. The US courts have definitively dismissed Apple’s appeal, confirming that the Californian firm must pay $634 million…
Read MoreGivaudan and Nestlé: a Challenging First Semester for the two Swiss Health Valley Powerhouses
Two of Switzerland’s biggest names in industry unveiled their half-year results on Thursday, and the stock market did not respond well. Givaudan and Nestlé, both based in the Lake Geneva region, saw their share prices fall sharply at the opening bell, driven by disappointing figures despite some encouraging signs. At Givaudan, the flavour and fragrance…
Read MoreLifeSpan Summit
The LifeSpan Summit is taking place from 14 to 16 October 2026 in Malaga, Spain The LifeSpan Summit is the premier customer-driven, business-led global gathering dedicated to transforming longevity innovation into real-world impact. Designed as an active environment for learning, exchange, and co-creation, the Summit brings together cross-sector leaders to explore the tools, business models, and technological breakthroughs shaping the future of…
Read MoreHilo Raises $19 Million and Launches Wearable Blood Pressure Monitor in the US
Hilo has launched Hilo Core, a wearable system designed to give people long-term blood pressure insights instead of one-off cuff readings. The company, based in Neuchâtel, Switzerland, is bringing the device to the US market starting today, available via Hilo.com and Amazon. Hilo Core pairs a lightweight wrist band with a mobile app and an…
Read MoreImmitra Bio Closed a CHF 2.4 Million Pre-Seed Financing Round
The ETHZ spinoff and Geneva-based company aims to replace complex stem cell transplantation procedures with a single injection, making potentially curative therapies more accessible to patients worldwide. CHF 2.25 million was provided by venture capital and private investors, with an additional CHF 150k secured through non-dilutive funding sources. The round was led by Backbone Ventures…
Read More